semaglutide binge eating disorder case report The rapid rise of GLP-1 receptor agonists presents a complex dilemma for clinicians managing patients with disorders. While these medications show potential in reducing eating behaviors by targeting brain reward Psychological and medical treatments for...

Its a permanent shift in how a growing segment of consumers approach food, influencing buying decisions for GLP-1 users and their families

Monitoring Vitamin D Levels Vitamin D is one of those things that a lot of people are low on, even without being on GLP-1 meds

Some individuals notice reduced appetite and weight loss within a few weeks, while for others, it may take several months

Secundino Cigarrn Guldris declares funding to conduct clinical trials from AstraZeneca, Bayer, Boehringer Ingelheim and Novo Nordisk (all to the FIDES Research Foundation) and payment of honoraria for lectures from AstraZeneca, Novo Nordisk , Baxter, Chiesi, ChemoCentrix, Clarion and Boehringer Ingelheim Josep M

10.2147/DDDT.S327378 84 PetersonC

We know about side effects such as nausea, vomiting and digestive problems, but what about longer-term outcomes